Skip to main content
JINLING PHARMACEUTICAL CO.,LTD logo

JINLING PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 000919 ISIN · CNE0000010W5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,771 across all filing types
Latest filing 2020-06-23 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 000919

About JINLING PHARMACEUTICAL CO.,LTD

https://www.jlyy1999.com

Jinling Pharmaceutical Co., Ltd. specializes in the research, development, manufacture, and sale of pharmaceutical products, with a focus on chemical drugs and traditional Chinese medicine preparations. The company’s product portfolio primarily targets cardiovascular and cerebrovascular diseases, anti-tumor treatments, and digestive system health. A prominent product in its lineup is the Mailuoning Injection, utilized for treating various vascular conditions. In addition to its manufacturing operations, the company is involved in the management and operation of medical institutions, integrating clinical services with pharmaceutical production. Its business model emphasizes the synergy between drug development and healthcare service delivery to provide integrated medical solutions.

Recent filings

Filing Released Lang Actions
第八届监事会第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from Jinling Pharmaceutical Co., Ltd. regarding the resolution of the first meeting of the eighth Supervisory Board. It details the meeting's convening, attendance, election of the Supervisory Board Chairman, and includes biographical information about the elected chairman. The document is short (1350 characters) and focuses on governance matters, specifically the election of a supervisory board chairman. There is no financial data, no mention of annual or interim reports, no earnings information, and no regulatory filings or certifications. The content fits the category of Board/Management Information, as it announces changes in the company's supervisory board leadership.
2020-06-23 Chinese
第八届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the first meeting of the eighth board of directors of Jinling Pharmaceutical Co., Ltd. It includes information about the election and appointment of the chairman, various board committees, and senior management positions, along with their terms and biographies. The document also confirms the attendance and voting results for each resolution. There is no financial data, earnings information, or report publication mentioned. The content focuses entirely on board and management changes and appointments. Therefore, this document fits the category of Board/Management Information (MANG). The document length is over 5,000 characters and contains substantive content, not just an announcement or notice, so it is not a Regulatory Filing or Report Publication Announcement.
2020-06-23 Chinese
监事会议事规则（2020年6月）
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Supervisory Board Meetings" of Jinling Pharmaceutical Co., Ltd., approved by the 2019 Annual General Meeting. It details the internal rules, procedures, powers, and responsibilities of the supervisory board, including meeting notices, proposal rules, voting procedures, and confidentiality. There is no financial data, earnings, audit results, or announcements of voting results. The content focuses on governance structure and internal board procedures. Therefore, this document fits the category of Governance Information (CGR). The document length is 3660 characters, which is not a brief announcement but a full set of governance rules.
2020-06-22 Chinese
董事会议事规则（2020年6月）
Governance Information Classification · 100% confidence The document is titled as the "Rules of Procedure for the Board of Directors" of Jinling Pharmaceutical Co., Ltd., approved by the 2019 Annual General Meeting. It details the structure, powers, meeting procedures, proposal rules, voting rules, and post-meeting responsibilities of the company's board of directors. It is a governance document outlining internal rules and procedures for the board rather than a financial report, announcement, or other regulatory filing. There is no financial data, earnings information, or voting results presented. The content fits the description of a Governance Information report, which details the company's internal rules, board structure, and governance practices.
2020-06-22 Chinese
股东大会议事规则（2020年6月）
Governance Information Classification · 95% confidence The document is titled as the "Rules of Procedure for the Shareholders' General Meeting" of Jinling Pharmaceutical Co., Ltd., approved at the 2019 Annual General Meeting. It details the procedures, powers, and regulations governing the shareholders' meetings, including convening, voting, proposals, and post-meeting announcements. It is a governance-related document outlining internal rules and processes for shareholder meetings rather than a report of financial results, voting outcomes, or announcements of meetings. It does not contain financial statements or results, nor is it a notice or announcement of a meeting or report publication. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2020-06-22 Chinese
2019年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2019 Annual General Meeting (AGM) of Jinling Pharmaceutical Co., Ltd. It details the procedures of the AGM, attendance, voting results on various proposals including financial reports, board elections, and amendments to company rules. The document focuses on the legality and validity of the AGM process and voting outcomes rather than presenting financial data or management discussion. It is not the annual report itself, nor an earnings release or management report. It is a legal opinion related to the AGM proceedings and voting results. Therefore, the document best fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (7920 characters) and content confirm it is a detailed voting result announcement rather than a brief notice or a report publication announcement.
2020-06-22 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.